Statins were originally developed as cholesterol reducing drugs, it was later discovered that they had pleiotropic effects, meaning an anti-inflammatory, antimicrobial, and anticancer effect. Statins inhibit NF kB activation and prevent release of inflammatory cytokines such as interleukin 6. Interleukin-6 and other inflammatory cytokines stimulate the cancers to grow and proliferate.

By blocking the mevalonate pathway with a statin blocks the Rho protein, thus inhibiting actin polymerization that is fundamental for the actin filament system. These filaments contract all elements in the muscle cells. In cancer cells, the actin filament system makes up the side of skeleton that regulates movement, migration, and cell adhesion. The statin drugs destabilized the state of skeleton of the cancer cells.

In addition, many cancer cells have upregulated HMG Co A an enzyme that is the rate limiting step and that mevalonate pathway. The statin drugs inhibit this pathway and cause a depletion of isoprenoids in cancer cells inducing mitochondrial mediated cell death.

Studies have shown the statins to be effective in the following cancer cell lines: Lymphoma, breast cancer, endometrial cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, lung cancer, rhabdomyosarcoma, melanoma, and colon cancer.

Statin drugs are oxidative phosphorylation inhibitors and should be used in combination and synergistically with other cancer pathways.

Combination therapy should always be used with a statin. It is well-known that statins deplete Q10. It needs to be supplemented

If you are interested in re-purposed drugs, evaluation of circulating cancer stem cells, low-dose metronomic genomic chemotherapy, natural substances, and cancer vaccines we can help.

Please call us at 727-330-3844